HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 138 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $6,439,000 | -0.8% | 161,452 | 0.0% | 2.55% | +35.7% |
| Q4 2021 | $6,492,000 | -5.4% | 161,452 | -4.2% | 1.88% | +41.0% |
| Q3 2021 | $6,859,000 | -86.6% | 168,604 | -85.1% | 1.33% | -81.6% |
| Q2 2021 | $51,293,000 | +8.9% | 1,129,551 | 0.0% | 7.24% | +13.5% |
| Q1 2021 | $47,091,000 | -37.4% | 1,129,551 | -35.9% | 6.38% | -7.3% |
| Q4 2020 | $75,258,000 | -4.2% | 1,762,072 | -41.0% | 6.88% | -57.7% |
| Q3 2020 | $78,539,000 | -16.9% | 2,988,532 | -15.2% | 16.26% | +3.9% |
| Q2 2020 | $94,482,000 | -25.5% | 3,524,141 | -50.0% | 15.65% | -42.5% |
| Q1 2020 | $126,799,000 | +1.5% | 7,048,282 | +0.0% | 27.23% | +35.1% |
| Q4 2019 | $124,932,000 | -17.0% | 7,046,385 | -27.4% | 20.15% | -10.7% |
| Q3 2019 | $150,541,000 | -18.2% | 9,706,087 | -9.4% | 22.56% | +4.0% |
| Q2 2019 | $184,049,000 | -18.9% | 10,712,970 | -24.0% | 21.68% | -36.0% |
| Q1 2019 | $226,894,000 | +10.0% | 14,092,771 | 0.0% | 33.85% | +20.4% |
| Q4 2018 | $206,177,000 | -19.5% | 14,092,771 | 0.0% | 28.12% | +68.9% |
| Q3 2018 | $256,066,000 | -12.2% | 14,092,771 | -18.5% | 16.64% | -29.0% |
| Q2 2018 | $291,656,000 | -15.4% | 17,288,450 | -1.7% | 23.42% | -6.2% |
| Q1 2018 | $344,642,000 | -3.3% | 17,592,771 | 0.0% | 24.96% | -18.4% |
| Q4 2017 | $356,430,000 | +16.6% | 17,592,771 | 0.0% | 30.57% | +58.6% |
| Q3 2017 | $305,586,000 | +23.3% | 17,592,771 | -9.0% | 19.28% | +53.1% |
| Q2 2017 | $247,805,000 | -1.0% | 19,329,538 | +0.1% | 12.59% | -13.9% |
| Q1 2017 | $250,198,000 | +31.2% | 19,305,403 | 0.0% | 14.61% | +42.1% |
| Q4 2016 | $190,737,000 | -18.2% | 19,305,403 | 0.0% | 10.28% | -5.3% |
| Q3 2016 | $233,209,000 | +40.0% | 19,305,403 | 0.0% | 10.86% | +25.1% |
| Q2 2016 | $166,606,000 | -11.3% | 19,305,403 | -2.6% | 8.68% | +18.2% |
| Q1 2016 | $187,784,000 | -45.4% | 19,829,337 | 0.0% | 7.34% | -46.5% |
| Q4 2015 | $343,642,000 | +29.0% | 19,829,337 | 0.0% | 13.73% | +29.6% |
| Q3 2015 | $266,308,000 | -40.5% | 19,829,337 | 0.0% | 10.60% | -9.5% |
| Q2 2015 | $447,746,000 | +58.2% | 19,829,337 | +0.1% | 11.71% | +47.0% |
| Q1 2015 | $282,975,000 | +48.0% | 19,816,162 | 0.0% | 7.96% | -8.8% |
| Q4 2014 | $191,226,000 | +6.0% | 19,816,162 | 0.0% | 8.73% | -22.4% |
| Q3 2014 | $180,327,000 | -7.9% | 19,816,162 | 0.0% | 11.25% | +20.6% |
| Q2 2014 | $195,784,000 | -22.2% | 19,816,162 | +0.1% | 9.33% | -16.4% |
| Q1 2014 | $251,547,000 | -15.2% | 19,791,286 | 0.0% | 11.15% | -21.0% |
| Q4 2013 | $296,671,000 | +35.8% | 19,791,286 | +0.1% | 14.12% | +27.5% |
| Q3 2013 | $218,385,000 | +38.9% | 19,781,286 | 0.0% | 11.08% | -70.6% |
| Q2 2013 | $157,261,000 | – | 19,781,286 | – | 37.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |